利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.014 秒)

    Interleukin 15 as selectable marker for gene transfer in lymphocytes
    4.
    发明授权
    Interleukin 15 as selectable marker for gene transfer in lymphocytes 有权

    公开(公告)号：US10351612B2

    公开(公告)日：2019-07-16

    申请号：US15269731

    申请日：2016-09-19

    申请人： CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS

    发明人： Kurt Schönfeld ,  Christiane Knopp ,  Winfried Wels

    IPC分类号： A61K35/12 ,  C07K14/54 ,  C07K14/725 ,  C07K14/705 ,  C12N15/85 ,  C12N15/86 ,  A61K35/17 ,  C07K16/18

    摘要： The present invention relates to the use of interleukin-15 (IL-15) as selectable marker for gene transfer, preferably of at least one gene of therapeutic interest, into a mammalian cell or cell line, in particular a human cell or cell line. The present invention furthermore relates to transgenic mammalian cells or cell lines expressing IL-15 as selectable marker and co-expressing at least one protein of interest encoded by at least one gene of interest, which is preferably a protein of therapeutic interest. The present invention is in particular suitable for chimeric antigen receptors (CARs) as the gene or protein of interest and their expression in lymphocytes. The transgenic mammalian cells and cell lines are furthermore suitable for use as a medicament, in particular in the treatment of cancer and in immunotherapy, such as adoptive, target-cell specific immunotherapy.

    CHIMERIC ANTIGEN RECEPTORS WITH AN OPTIMIZED HINGE REGION
    5.
    发明申请
    CHIMERIC ANTIGEN RECEPTORS WITH AN OPTIMIZED HINGE REGION 有权
    具有优化的HINGE区域的CHIMERIC抗原受体

    公开(公告)号：US20130280285A1

    公开(公告)日：2013-10-24

    申请号：US13821491

    申请日：2011-09-06

    申请人： Kurt Schönfeld ,  Christiane Knopp ,  Winfried Wels

    发明人： Kurt Schönfeld ,  Christiane Knopp ,  Winfried Wels

    IPC分类号： C07K16/46 ,  C07K14/705 ,  C07K14/725

    CPC分类号： C07K16/46 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K16/32 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2319/00

    摘要： The present invention relates to multi-functional proteins which comprise (i) a signal peptide, (ii) a target specific recognition domain, (iii) a linker region, connecting domain (ii) and domain (iv) which comprises a specific modified hinge region of the human CD8 alpha-chain, and (iv) an effector domain. The present invention furthermore relates to nucleic acids encoding the proteins, expression constructs for expressing the protein in a host cell and host cells. The proteins of the invention are chimeric antigen receptors with an optimized linker or hinge region that are suitable for generating target-specific effector cells, for use as a medicament, in particular in the treatment of cancer and in adoptive, target-cell specific immunotherapy.

    摘要翻译： 本发明涉及多功能蛋白质，其包含（i）信号肽，（ii）靶特异性识别结构域，（iii）连接区，连接结构域（ii）和结构域（iv），其包含特定修饰的铰链 人类CD8α链的区域，和（iv）效应结构域。 本发明还涉及编码蛋白质的核酸，用于在宿主细胞和宿主细胞中表达蛋白质的表达构建体。 本发明的蛋白质是嵌合抗原受体，其具有适于产生靶特异性效应细胞的优化接头或铰链区，用作药物，特别是用于治疗癌症和过继性靶细胞特异性免疫疗法。

    PERIOSTIN COMPOUNDS FOR THE TREATMENT OF HAEMATOLOGICAL COMPLICATIONS
    6.
    发明申请
    PERIOSTIN COMPOUNDS FOR THE TREATMENT OF HAEMATOLOGICAL COMPLICATIONS 有权

    公开(公告)号：US20210261638A1

    公开(公告)日：2021-08-26

    申请号：US17260681

    申请日：2019-07-18

    申请人： Chemotherapeutisches Forschungsinstitut Georg-speyer-Haus

    发明人： Daniela S. Krause ,  Divij Verma

    IPC分类号： C07K14/51 ,  A61K35/28 ,  C12N5/0789

    摘要： The present invention pertains to periostin compounds for use in the prevention and treatment of haematological complications, such as adverse events from therapy or haematological diseases. In context of the present invention a therapeutic was developed for enhancing haematopoiesis in patients and to support haematopoietic stem cell (HSC) transplantation (HSCT) by administration of periostin compounds to patients or stem cell donors, or by contacting HSC directly with periostin compounds, for example ex vivo, to improve a transplant HSC preparation. The present invention provides periostin derived compounds such as polypeptides, peptides, nucleic acids, and other periostin-derived agents, that are used both in therapeutic applications and for improving haematopoiesis, for example in stem cell donor subjects or to treat HSC in vitro.

    Interleukin 15 as Selectable Marker for Gene Transfer in Lymphocytes
    8.
    发明申请
    Interleukin 15 as Selectable Marker for Gene Transfer in Lymphocytes 有权
    白细胞介素15作为淋巴细胞基因转移的可选标记

    公开(公告)号：US20130280221A1

    公开(公告)日：2013-10-24

    申请号：US13821474

    申请日：2011-09-06

    申请人： Kurt Schonfeld ,  Christiane Knopp ,  Winfried Wels

    发明人： Kurt Schonfeld ,  Christiane Knopp ,  Winfried Wels

    IPC分类号： C12N15/85

    CPC分类号： C07K14/5443 ,  A61K35/17 ,  A61K2035/124 ,  C07K14/7051 ,  C07K14/70517 ,  C07K16/18 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/74 ,  C12N15/85 ,  C12N15/86 ,  C12N2740/16043

    摘要： The present invention relates to the use of interleukin-15 (IL-15) as selectable marker for gene transfer, preferably of at least one gene of therapeutic interest, into a mammalian cell or cell line, in particular a human cell or cell line. The present invention furthermore relates to transgenic mammalian cells or cell lines expressing IL-15 as selectable marker and co-expressing at least one protein of interest encoded by at least one gene of interest, which is preferably a protein of therapeutic interest. The present invention is in particular suitable for chimeric antigen receptors (CARs) as the gene or protein of interest and their expression in lymphocytes. The transgenic mammalian cells and cell lines are furthermore suitable for use as a medicament, in particular in the treatment of cancer and in immunotherapy, such as adoptive, target-cell specific immunotherapy.

    摘要翻译： 本发明涉及将白细胞介素-15（IL-15）作为选择性标记用于哺乳动物细胞或细胞系，特别是人细胞或细胞系中的基因转移，优选至少一种具有治疗意义的基因的选择性标记。 本发明还涉及表达IL-15作为选择性标记的转基因哺乳动物细胞或细胞系，并共​​同表达由至少一种目的基因编码的至少一种目标蛋白质，其最好是治疗性兴趣的蛋白质。 本发明特别适用于感兴趣的基因或蛋白质的嵌合抗原受体（CAR）及其在淋巴细胞中的表达。 此外，转基因哺乳动物细胞和细胞系适合用作药物，特别是用于治疗癌症和免疫疗法，例如过继性靶细胞特异性免疫疗法。